Pulmatrix Enters Cross License Deal with MannKind Corporation
Wednesday, 29 May 2024, 09:56
Pulmatrix Announces Cross License Agreement
The pharmaceutical industry saw a significant development with Pulmatrix entering into a cross license agreement with MannKind Corporation. This strategic move underscores the companies' commitment to fostering innovation and collaboration within the healthcare sector.
Transfer of Laboratory to MannKind Corporation
- This cross license agreement also involves the transfer of laboratory facilities from Pulmatrix to MannKind Corporation, indicating a deeper level of partnership and shared resources.
Conclusion: The collaboration between Pulmatrix and MannKind Corporation is poised to drive progress and create new opportunities in pharmaceutical research and product development.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.